人表皮生长因子受体2在三阴性早期/局部晚期乳腺癌患者中的表达及与疗效和复发转移的关系  

Expression of human epidermal growth factor receptor 2 in patients with triplenegative early/locally advanced breast cancer and its relationship with efficacy,recurrent, and metastasis

作　　者：陈凯旋 黄兴伟 孙聪玲 李荣 黎军和[4] CHEN Kaixuan;HUANG Xingwei;SUN Congling;LI Rong;LI Junhe(Department of Breast Surgery,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Surgery Anesthesiology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Pathology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Medical Oncology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院乳腺外科,江西赣州341000 [2]赣州市肿瘤医院手术麻醉科,江西赣州341000 [3]赣州市肿瘤医院病理科,江西赣州341000 [4]南昌大学第一附属医院肿瘤内科,南昌330006

出　　处：《癌症进展》2023年第2期142-145,149,共5页Oncology Progress

摘　　要：目的 探讨人表皮生长因子受体2(HER2)在三阴性早期/局部晚期乳腺癌患者中的表达及与疗效和复发转移的关系。方法 收集接受新辅助化疗的98例三阴性早期/局部晚期乳腺癌患者的临床资料,分析不同HER2表达水平患者的临床特征,采用二元Logistic回归分析和Cox回归分析对三阴性早期/局部晚期乳腺癌患者完全缓解和预后的影响因素进行分析。结果 HER2低表达患者中腋窝淋巴结转移及术后淋巴结分期为N3期患者的比例均高于HER2表达为0的患者,差异均有统计学意义(P﹤0.05)。临床分期为cT_(3~4)期、HER2低表达均是三阴性早期/局部晚期乳腺癌患者完全缓解率的危险因素(P﹤0.01)。新辅助化疗后非完全缓解、HER2表达较高、术后淋巴结分期较高均是三阴性早期/局部晚期乳腺癌患者无病生存率(DFS)的危险因素(P﹤0.05)。结论临床分期为cT_(3~4)期、HER2低表达均是三阴性早期/局部晚期乳腺癌患者完全缓解的影响因素,且新辅助化疗后非完全缓解、HER2表达较高、术后淋巴结分期较高的患者预后较差,HER2表达水平可作为预测三阴性早期/局部晚期乳腺癌患者疗效及复发转移的指标。Objective To investigate the expression of human epidermal growth factor receptor 2(HER2) in patients with triple-negative early/locally advanced breast cancer and its relationship with efficacy, recurrent, and metastasis.Method The clinical data were collected from 98 patients with triple-negative early/locally advanced breast cancer who received neoadjuvant chemotherapy. The clinical features of patients with different HER2 expression levels were analyzed. Binary Logistic regression analysis and Cox regression analysis were built to analyze the influencing factors for complete response and prognosis in patients with triple-negative early/locally advanced breast cancer. Result The proportions of patients with low HER2 expression with axillary lymph node metastasis and postoperative lymph node stage N3were higher than those of patients with HER2 expression of 0, the differences were statistically significant(P<0.05).The clinical stage of cT_(3-4) and low expression of HER2 were risk factors for complete response in patients with triple-negative early/locally advanced breast cancer(P<0.01). Non-complete response after the neoadjuvant chemotherapy, HER2high expression, and high postoperative lymph node staging were all risk factors for disease-free survival(DFS) in patients with triple-negative early/locally advanced breast cancer(P<0.05). Conclusion Clinical stage of cT_(3-4) and low-expression of HER2 were influencing factors for patients with triple-negative early/locally advanced breast cancer who achieved complete response. Patients with non-complete response after the neoadjuvant chemotherapy, HER2 high expression, and high postoperative lymph node staging tend to have a poor prognosis. HER2 expression level could be used as an indicator to predict the efficacy, recurrence and metastasis of patients with triple-negative early/locally advanced breast cancer.

关 键 词：三阴性早期/局部晚期乳腺癌 人表皮生长因子受体2 转移 复发 

分 类 号：R737.9[医药卫生—肿瘤]